Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients

By  

Current HIV Research, Vol. 7, Iss. 4, 2009-07 ,pp. : 425-433

Bentham Science Publishers

Access to resources Recommend Favorite

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y 12 inhibitor: A single ascending dose study in healthy humans†

By Asai Fumitoshi   Jakubowski Joseph A.   Naganuma Hideo   Brandt John T.   Matsushima Nobuko   Hirota Takashi   Freestone Stephen   Winters Kenneth J.  

Platelets, Vol. 17, Iss. 4, 2006-06 ,pp. : 209-217

Informa Healthcare

Access to resources Recommend Favorite

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance

By Babrzadeh Farbod   Varghese Vici   Pacold Mary   Liu Tommy F.   Nyrén Pål   Schiffer Celia   Fessel W. Jeffrey   Shafer Robert W.  

Journal of Antimicrobial Chemotherapy, Vol. 68, Iss. 2, 2013-02 ,pp. : 414-418

Oxford University Press

Access to resources Recommend Favorite

Severe Impairment of Endothelial Function with the HIV-1 Protease Inhibitor Indinavir is not Mediated by Insulin Resistance in Healthy Subjects

By Dubé Michael   Gorski Jude   Shen Changyu  

Cardiovascular Toxicology, Vol. 8, Iss. 1, 2008-03 ,pp. : 15-22

Humana Press, Inc

Access to resources Recommend Favorite

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y 12 inhibitor: A multiple-dose study in healthy humans†

By Matsushima Nobuko   Jakubowski Joseph A.   Asai Fumitoshi   Naganuma Hideo   Brandt John T.   Hirota Takashi   Freestone Stephen   Winters Kenneth J.  

Platelets, Vol. 17, Iss. 4, 2006-06 ,pp. : 218-226

Informa Healthcare

Access to resources Recommend Favorite